MRM
MEDIROM Healthcare Technologies Inc.
Personal Products & Services
Market Cap$6M
5Y Perf.-91.9%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
MRM vs MNMD vs HIMS vs CMPS
Revenue, margins, valuation, and 5-year total return — side by side.
MNMD
Mind Medicine (MindMed) Inc.
Biotechnology
Market Cap$2.04B
5Y Perf.-58.7%
HIMS
Hims & Hers Health, Inc.
Medical - Equipment & Services
Market Cap$6.63B
5Y Perf.+75.8%
CMPS
COMPASS Pathways plc
Medical - Care Facilities
Market Cap$902M
5Y Perf.-80.3%
MRM vs MNMD vs HIMS vs CMPS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | MRM | MNMD | HIMS | CMPS |
|---|---|---|---|---|
| Industry | Personal Products & Services | Biotechnology | Medical - Equipment & Services | Medical - Care Facilities |
| Market Cap | $6M | $2.04B | $6.63B | $902M |
| Revenue (TTM) | $11.91B | $0.00 | $2.35B | $0.00 |
| Net Income (TTM) | $615M | $-238M | $128M | $-288M |
| Gross Margin | 26.4% | — | 69.7% | — |
| Operating Margin | -0.9% | — | 4.6% | — |
| Forward P/E | 6.4x | — | 51.5x | — |
| Total Debt | $3.96B | $0.00 | $1.12B | $21M |
| Cash & Equiv. | $329M | $258M | $229M | $150M |
MRM vs MNMD vs HIMS vs CMPS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
MRM
MNMD
HIMS
CMPS
| Stock | Dec 20 | May 26 | Return |
|---|---|---|---|
| MEDIROM Healthcare … (MRM) | 100 | 8.1 | -91.9% |
| Mind Medicine (Mind… (MNMD) | 100 | 41.3 | -58.7% |
| Hims & Hers Health,… (HIMS) | 100 | 175.8 | +75.8% |
| COMPASS Pathways plc (CMPS) | 100 | 19.7 | -80.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: MRM vs MNMD vs HIMS vs CMPS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: MRM and HIMS are tied at the top with 2 categories each — the right choice depends on your priorities. Hims & Hers Health, Inc. is the stronger pick specifically for growth and revenue expansion and profitability and margin quality. MNMD and CMPS also each lead in at least one category. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
MRM
MEDIROM Healthcare Technologies Inc.
The Value Play
MRM has the current edge in this matchup, primarily because of its strength in value and efficiency.
- Better valuation composite
- 11.8% ROA vs CMPS's -106.8%
Best for: value and efficiency
MNMD
Mind Medicine (MindMed) Inc.
The Long-Run Compounder
MNMD is the clearest fit if your priority is long-term compounding and defensive.
- 5.1% 10Y total return vs HIMS's 161.9%
- Beta 1.68, current ratio 6.29x
- +214.0% vs HIMS's -51.0%
Best for: long-term compounding and defensive
HIMS
Hims & Hers Health, Inc.
The Growth Play
HIMS is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 59.0%, EPS growth -3.8%, 3Y rev CAGR 64.5%
- 59.0% revenue growth vs MNMD's -96.9%
- 5.5% margin vs MNMD's 1.2%
Best for: growth exposure
CMPS
COMPASS Pathways plc
The Income Pick
CMPS is the clearest fit if your priority is income & stability and sleep-well-at-night.
- beta 1.33
- Lower volatility, beta 1.33, current ratio 0.77x
- Beta 1.33 vs HIMS's 2.40
Best for: income & stability and sleep-well-at-night
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | HIMS | 59.0% revenue growth vs MNMD's -96.9% |
| Value | MRM | Better valuation composite |
| Quality / Margins | HIMS | 5.5% margin vs MNMD's 1.2% |
| Stability / Safety | CMPS | Beta 1.33 vs HIMS's 2.40 |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | MNMD | +214.0% vs HIMS's -51.0% |
| Efficiency (ROA) | MRM | 11.8% ROA vs CMPS's -106.8% |
MRM vs MNMD vs HIMS vs CMPS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2024
Segment breakdown not available.
Segment breakdown not available.
Segment breakdown not available.
MRM vs MNMD vs HIMS vs CMPS — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLMRMLAGGINGCMPS
Who Leads Where
MRM leads in 2 of 6 categories
HIMS leads 1 • MNMD leads 1 • CMPS leads 0 • 1 tied
Explore the data ↓CMPSCOMPASS Pathways plc
0leads
HIMSHims & Hers Health, I…
1leads
MNMDMind Medicine (MindMe…
1leads
MRMMEDIROM Healthcare Te…
2leads
6 Total Categories
CATEGORYLEADERvs MNMDvs HIMSMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
HIMS5/6
Valuation MetricsMultiples, price ratios, and targets
MRM3/4
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
MRM4/9
Total Returns1Y, 3Y, 5Y total returns with dividends
MNMD5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
HIMS leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
MRM and CMPS operate at a comparable scale, with $11.9B and $0 in trailing revenue. Profitability is closely matched — net margins range from 5.5% (HIMS) to 5.2% (MRM). On growth, HIMS holds the edge at +28.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | MRMMEDIROM Healthcar… | MNMDMind Medicine (Mi… | HIMSHims & Hers Healt… | CMPSCOMPASS Pathways … |
|---|---|---|---|---|
| RevenueTrailing 12 months | $11.9B | $0 | $2.3B | $0 |
| EBITDAEarnings before interest/tax | $338M | -$191M | $164M | -$179M |
| Net IncomeAfter-tax profit | $615M | -$238M | $128M | -$288M |
| Free Cash FlowCash after capex | -$2.0B | -$174M | $73M | -$157M |
| Gross MarginGross profit ÷ Revenue | +26.4% | — | +69.7% | — |
| Operating MarginEBIT ÷ Revenue | -0.9% | — | +4.6% | — |
| Net MarginNet income ÷ Revenue | +5.2% | — | +5.5% | — |
| FCF MarginFCF ÷ Revenue | -16.8% | — | +3.1% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | -99.4% | — | +28.4% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +99.5% | -163.0% | -27.3% | -58.7% |
HIMS leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
MRM leads this category, winning 3 of 4 comparable metrics.
Valuation Metrics
At 6.4x trailing earnings, MRM trades at a 87% valuation discount to HIMS's 50.3x P/E. On an enterprise value basis, MRM's 16.7x EV/EBITDA is more attractive than HIMS's 42.7x.
| Metric | MRMMEDIROM Healthcar… | MNMDMind Medicine (Mi… | HIMSHims & Hers Healt… | CMPSCOMPASS Pathways … |
|---|---|---|---|---|
| Market CapShares × price | $6M | $2.0B | $6.6B | $902M |
| Enterprise ValueMkt cap + debt − cash | $29M | $1.8B | $7.5B | $774M |
| Trailing P/EPrice ÷ TTM EPS | 6.36x | -10.04x | 50.32x | -3.05x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 51.51x | — |
| PEG RatioP/E ÷ EPS growth rate | 0.13x | — | — | — |
| EV / EBITDAEnterprise value multiple | 16.75x | — | 42.68x | — |
| Price / SalesMarket cap ÷ Revenue | 0.11x | — | 2.82x | — |
| Price / BookPrice ÷ Book value/share | 0.89x | 5.56x | 12.25x | — |
| Price / FCFMarket cap ÷ FCF | — | — | 89.61x | — |
MRM leads this category, winning 3 of 4 comparable metrics.
Profitability & Efficiency
MRM leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
MRM delivers a 2.4% return on equity — every $100 of shareholder capital generates $2 in annual profit, vs $-3 for CMPS. HIMS carries lower financial leverage with a 2.07x debt-to-equity ratio, signaling a more conservative balance sheet compared to MRM's 3.33x. On the Piotroski fundamental quality scale (0–9), MRM scores 6/9 vs CMPS's 2/9, reflecting solid financial health.
| Metric | MRMMEDIROM Healthcar… | MNMDMind Medicine (Mi… | HIMSHims & Hers Healt… | CMPSCOMPASS Pathways … |
|---|---|---|---|---|
| ROE (TTM)Return on equity | +2.4% | -102.5% | +23.7% | -3.4% |
| ROA (TTM)Return on assets | +11.8% | -70.7% | +6.0% | -106.8% |
| ROICReturn on invested capital | -0.3% | -3.9% | +10.7% | — |
| ROCEReturn on capital employed | -0.5% | -52.2% | +10.9% | -2.5% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 3 | 4 | 2 |
| Debt / EquityFinancial leverage | 3.33x | — | 2.07x | — |
| Net DebtTotal debt minus cash | $3.6B | -$258M | $892M | -$129M |
| Cash & Equiv.Liquid assets | $329M | $258M | $229M | $150M |
| Total DebtShort + long-term debt | $4.0B | $0 | $1.1B | $21M |
| Interest CoverageEBIT ÷ Interest expense | 0.56x | -21.81x | — | -52.40x |
MRM leads this category, winning 4 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
MNMD leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in HIMS five years ago would be worth $23,764 today (with dividends reinvested), compared to $1,176 for MRM. Over the past 12 months, MNMD leads with a +214.0% total return vs HIMS's -51.0%. The 3-year compound annual growth rate (CAGR) favors MNMD at 82.7% vs MRM's -41.5% — a key indicator of consistent wealth creation.
| Metric | MRMMEDIROM Healthcar… | MNMDMind Medicine (Mi… | HIMSHims & Hers Healt… | CMPSCOMPASS Pathways … |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -40.8% | +51.7% | -23.2% | +43.4% |
| 1-Year ReturnPast 12 months | +47.9% | +214.0% | -51.0% | +151.1% |
| 3-Year ReturnCumulative with dividends | -80.0% | +510.3% | +116.6% | +11.0% |
| 5-Year ReturnCumulative with dividends | -88.2% | -57.9% | +137.6% | -72.4% |
| 10-Year ReturnCumulative with dividends | -92.3% | +512.1% | +161.9% | -67.6% |
| CAGR (3Y)Annualised 3-year return | -41.5% | +82.7% | +29.4% | +3.5% |
MNMD leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — MRM and MNMD each lead in 1 of 2 comparable metrics.
Risk & Volatility
MRM is the less volatile stock with a -0.54 beta — it tends to amplify market swings less than HIMS's 2.40 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MNMD currently trades 98.1% from its 52-week high vs MRM's 26.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | MRMMEDIROM Healthcar… | MNMDMind Medicine (Mi… | HIMSHims & Hers Healt… | CMPSCOMPASS Pathways … |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | -0.54x | 1.68x | 2.40x | 1.33x |
| 52-Week HighHighest price in past year | $4.45 | $21.09 | $70.43 | $10.21 |
| 52-Week LowLowest price in past year | $0.72 | $6.03 | $13.74 | $2.25 |
| % of 52W HighCurrent price vs 52-week peak | +26.1% | +98.1% | +36.4% | +92.0% |
| RSI (14)Momentum oscillator 0–100 | 49.2 | 64.9 | 54.5 | 68.1 |
| Avg Volume (50D)Average daily shares traded | 378K | 792K | 34.9M | 3.7M |
Evenly matched — MRM and MNMD each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: MNMD as "Buy", HIMS as "Hold", CMPS as "Buy". Consensus price targets imply 89.9% upside for CMPS (target: $18) vs -3.3% for MNMD (target: $20).
| Metric | MRMMEDIROM Healthcar… | MNMDMind Medicine (Mi… | HIMSHims & Hers Healt… | CMPSCOMPASS Pathways … |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Hold | Buy |
| Price TargetConsensus 12-month target | — | $20.00 | $29.67 | $17.83 |
| # AnalystsCovering analysts | — | 1 | 19 | 13 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +1.4% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
MRM leads in 2 of 6 categories (Valuation Metrics, Profitability & Efficiency). HIMS leads in 1 (Income & Cash Flow). 1 tied.
Best OverallMEDIROM Healthcare Technolo… (MRM)Leads 2 of 6 categories
Loading custom metrics...
MRM vs MNMD vs HIMS vs CMPS: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is MRM or MNMD or HIMS or CMPS a better buy right now?
For growth investors, Hims & Hers Health, Inc.
(HIMS) is the stronger pick with 59. 0% revenue growth year-over-year, versus 21. 5% for MEDIROM Healthcare Technologies Inc. (MRM). MEDIROM Healthcare Technologies Inc. (MRM) offers the better valuation at 6. 4x trailing P/E, making it the more compelling value choice. Analysts rate Mind Medicine (MindMed) Inc. (MNMD) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — MRM or MNMD or HIMS or CMPS?
On trailing P/E, MEDIROM Healthcare Technologies Inc.
(MRM) is the cheapest at 6. 4x versus Hims & Hers Health, Inc. at 50. 3x.
03Which is the better long-term investment — MRM or MNMD or HIMS or CMPS?
Over the past 5 years, Hims & Hers Health, Inc.
(HIMS) delivered a total return of +137. 6%, compared to -88. 2% for MEDIROM Healthcare Technologies Inc. (MRM). Over 10 years, the gap is even starker: MNMD returned +512. 1% versus MRM's -92. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — MRM or MNMD or HIMS or CMPS?
By beta (market sensitivity over 5 years), MEDIROM Healthcare Technologies Inc.
(MRM) is the lower-risk stock at -0. 54β versus Hims & Hers Health, Inc. 's 2. 40β — meaning HIMS is approximately -541% more volatile than MRM relative to the S&P 500. On balance sheet safety, Hims & Hers Health, Inc. (HIMS) carries a lower debt/equity ratio of 2% versus 3% for MEDIROM Healthcare Technologies Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — MRM or MNMD or HIMS or CMPS?
By revenue growth (latest reported year), Hims & Hers Health, Inc.
(HIMS) is pulling ahead at 59. 0% versus 21. 5% for MEDIROM Healthcare Technologies Inc. (MRM). On earnings-per-share growth, the picture is similar: MEDIROM Healthcare Technologies Inc. grew EPS 28. 1% year-over-year, compared to -1273. 3% for Mind Medicine (MindMed) Inc.. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — MRM or MNMD or HIMS or CMPS?
Hims & Hers Health, Inc.
(HIMS) is the more profitable company, earning 5. 5% net margin versus 0. 0% for COMPASS Pathways plc — meaning it keeps 5. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HIMS leads at 5. 2% versus -0. 2% for MRM. At the gross margin level — before operating expenses — HIMS leads at 59. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is MRM or MNMD or HIMS or CMPS more undervalued right now?
Analyst consensus price targets imply the most upside for CMPS: 89.
9% to $17. 83.
08Which pays a better dividend — MRM or MNMD or HIMS or CMPS?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is MRM or MNMD or HIMS or CMPS better for a retirement portfolio?
For long-horizon retirement investors, MEDIROM Healthcare Technologies Inc.
(MRM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 54)). Hims & Hers Health, Inc. (HIMS) carries a higher beta of 2. 40 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MRM: -92. 3%, HIMS: +161. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between MRM and MNMD and HIMS and CMPS?
These companies operate in different sectors (MRM (Consumer Cyclical) and MNMD (Healthcare) and HIMS (Healthcare) and CMPS (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: MRM is a small-cap high-growth stock; MNMD is a small-cap quality compounder stock; HIMS is a small-cap high-growth stock; CMPS is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.